---
title: "Truist Financial Sticks to Its Buy Rating for Climb Bio (CLYM)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295232158.md"
description: "Truist Financial analyst Danielle Brill maintained a Buy rating on Climb Bio (CLYM) with a $25 price target. Brill, a 5-star analyst in the Healthcare sector, has a strong track record. The broader analyst consensus for Climb Bio is also a Strong Buy, with an average price target of $23.43."
datetime: "2026-08-07T12:06:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295232158.md)
  - [en](https://longbridge.com/en/news/295232158.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295232158.md)
generator: "portal-rs"
---

# Truist Financial Sticks to Its Buy Rating for Climb Bio (CLYM)

Truist Financial analyst Danielle Brill maintained a Buy rating on Climb Bio today and set a price target of $25.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Brill is a 5-star analyst with an average return of 16.6% and a 56.40% success rate. Brill covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Biogen, and Insmed.

Currently, the analyst consensus on Climb Bio is a Strong Buy with an average price target of $23.43.

### Related Stocks

- [CLYM.US](https://longbridge.com/en/quote/CLYM.US.md)
- [TFC.US](https://longbridge.com/en/quote/TFC.US.md)
- [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md)
- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)
- [INSM.US](https://longbridge.com/en/quote/INSM.US.md)

## Related News & Research

- [Is Climb Bio’s (CLYM) Mixed Loss Trends Revealing a Shift in Its Investment Story?](https://longbridge.com/en/news/296222919.md)
- [Climb Bio: Unique APRIL Inhibitor Profile Supports Buy Rating and Unchanged $20 Price Target](https://longbridge.com/en/news/293376610.md)
- [Attovia Therapeutics, Inc. (ATTO) Initiated with a Buy at RBC Capital](https://longbridge.com/en/news/297470988.md)
- [Insiders Are Betting Big on These 3 Healthcare Stocks](https://longbridge.com/en/news/297547381.md)
- [Vaxcyte management to join Wells Fargo healthcare conference fireside chat](https://longbridge.com/en/news/297227027.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**